SCHEMBL3268523

SCHEMBL3268523

CC(C)(C)OC(=O)N1CCN(c2cc(-c3cccc(F)c3F)ncn2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMARCA2 P51531 1/20 0.48
SMARCA4 P51532 1/20 0.48
PBRM1 Q86U86 1/20 0.48
MAP4K4 O95819 1/20 0.47
GPR119 Q8TDV5 5/20 0.46
CKS1B P61024 2/20 0.46
SKP1 P63208 2/20 0.46
SKP2 Q13309 2/20 0.46
FAAH O00519 1/20 0.45
CYP1A2 P05177 3/20 0.44
CYP2C19 P33261 2/20 0.44
KIT P10721 2/20 0.44
PDK2 Q15119 1/20 0.43
CXCR2 P25025 1/20 0.43
ALOX15 P16050 1/20 0.42
RET P07949 1/20 0.41
ITGB2 P05107 1/20 0.41
ICAM1 P05362 1/20 0.41
ITGAL P20701 1/20 0.41
CNR1 P21554 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3268033 0.92 SMARCA2 (0.53) SMARCA2SMARCA4PBRM1MAP4K4GPR119
SCHEMBL3267984 0.84 FAAH (0.59) SMARCA2SMARCA4PBRM1MAP4K4GPR119
SCHEMBL3268524 0.84 CKS1B (0.48) SMARCA2SMARCA4PBRM1MAP4K4GPR119
SCHEMBL3268387 0.84 LRRK2 (0.50) SMARCA2SMARCA4PBRM1MAP4K4GPR119
SCHEMBL3269829 0.82 CKS1B (0.52) SMARCA2SMARCA4PBRM1MAP4K4GPR119
SCHEMBL3270107 0.81 MAP4K4 (0.50) SMARCA2SMARCA4PBRM1MAP4K4GPR119
SCHEMBL3273530 0.81 CKS1B (0.62) SMARCA2SMARCA4PBRM1MAP4K4GPR119
SCHEMBL3269283 0.80 CKS1B (0.48) SMARCA2SMARCA4PBRM1MAP4K4GPR119
SCHEMBL3775088 0.78 MAPT (0.50) SMARCA2SMARCA4PBRM1CKS1BSKP1
SCHEMBL2386105 0.77 GBA1 (0.54) SMARCA2SMARCA4PBRM1MAP4K4GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100234389-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-16 US disclosed
EP-2199282-A1 AMIDE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-06-23 EP disclosed
US-20090163508-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234389-A1 AMIDE COMPOUND FAAH, FAAH2, NAAA SMARCA2 2545/4885SMARCA4 2493/4885PBRM1 4191/4885
US-20090163508-A1 AMIDE COMPOUND FAAH, FAAH2, NAAA SMARCA2 2545/4885SMARCA4 2493/4885PBRM1 4191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.